TAT Congress series

THE HOME OF PHASE 1 IN ONCOLOGY !

TAT provides an annual forum for in-depth discussion of emerging targeted agents for the treatment of cancer. The TAT series was established in 2002 and was offered by the NDDO Education Foundation until 2013, in a partnership with the European Society for Medical Oncology (ESMO). The National Cancer Institute (NCI) co-sponsred all meetings held between 2008 and 2013.

TAT meetings are characterized by:

• Focus on emerging innovative cancer therapeutics in phase 1 or about to enter phase 1 clinical studies
• Faculty encompassing the world's leading oncology phase 1 investigatorst and 
• Completely plenary program allowing delegates to focus and not miss anything;
• Opportunities to present and discuss new research findings in a setting with the world's experts
• Medium-sized meetings with excellent opportunities for interaction and networking between stakeholders in oncology drug development
• Attention to methodological and regulatory issues in anticancer drug development
• Educational value for medical specialists and drug development professionals in oncology

TAT meetings attract a mix of professionals with different backgrounds and roles in academia, pharma, biotech,diagnostic industry and governmental agencies.

TAT congresses are held at varying places in Europe and USA, usually in the first weeks of March. The next meeting will be TAT 2014 in Washington DC, March 5-7, 2014.